CORMEDIX ($CRMD) posted quarterly earnings results for Q4 2025 on Thursday, March 5th. The company reported earnings of $0.61 per share, missing estimates of $0.83 by $0.22. The company also reported revenue of $128,620,000, missing estimates of $129,562,440 by $-942,440.
You can see Quiver Quantitative's $CRMD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CORMEDIX Insider Trading Activity
CORMEDIX insiders have traded $CRMD stock on the open market 15 times in the past 6 months. Of those trades, 1 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $CRMD stock by insiders over the last 6 months:
- JANET DILLIONE has made 0 purchases and 5 sales selling 147,000 shares for an estimated $1,547,555.
- JOSEPH TODISCO (Chief Executive Officer) has made 0 purchases and 2 sales selling 80,000 shares for an estimated $1,010,000.
- ELIZABETH HURLBURT (Chief Operating Officer) has made 0 purchases and 2 sales selling 53,997 shares for an estimated $711,817.
- KAUFMAN BETH ZELNICK (Chief Legal Officer) has made 0 purchases and 2 sales selling 50,000 shares for an estimated $670,264.
- STEVEN W LEFKOWITZ sold 40,000 shares for an estimated $475,200
- ALAN W DUNTON has made 0 purchases and 2 sales selling 30,000 shares for an estimated $391,300.
- MYRON KAPLAN purchased 25,000 shares for an estimated $275,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CORMEDIX Hedge Fund Activity
We have seen 114 institutional investors add shares of CORMEDIX stock to their portfolio, and 113 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 4,774,076 shares (+954.8%) to their portfolio in Q4 2025, for an estimated $55,522,503
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 2,215,889 shares (-66.7%) from their portfolio in Q4 2025, for an estimated $25,770,789
- MARSHALL WACE, LLP removed 1,507,232 shares (-43.4%) from their portfolio in Q4 2025, for an estimated $17,529,108
- CITADEL ADVISORS LLC removed 1,396,937 shares (-81.4%) from their portfolio in Q4 2025, for an estimated $16,246,377
- GHISALLO CAPITAL MANAGEMENT LLC removed 750,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,722,500
- ANSON FUNDS MANAGEMENT LP removed 725,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,431,750
- QUBE RESEARCH & TECHNOLOGIES LTD removed 637,497 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $7,414,090
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CORMEDIX Analyst Ratings
Wall Street analysts have issued reports on $CRMD in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 02/11/2026
- HC Wainwright & Co. issued a "Buy" rating on 01/23/2026
- Needham issued a "Buy" rating on 01/08/2026
- RBC Capital issued a "Outperform" rating on 10/21/2025
- JMP Securities issued a "Market Outperform" rating on 09/09/2025
To track analyst ratings and price targets for CORMEDIX, check out Quiver Quantitative's $CRMD forecast page.
CORMEDIX Price Targets
Multiple analysts have issued price targets for $CRMD recently. We have seen 5 analysts offer price targets for $CRMD in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $14.0 on 02/11/2026
- Brandon Folkes from HC Wainwright & Co. set a target price of $13.0 on 01/23/2026
- Leonid Timashev from RBC Capital set a target price of $13.0 on 01/21/2026
- Serge Belanger from Needham set a target price of $15.0 on 01/08/2026
- Jason N. Butler from JMP Securities set a target price of $22.0 on 09/09/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
